白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2011年
12期
747-749
,共3页
贾庆瑞%葛祥花%徐彧%李长龙%管滨
賈慶瑞%葛祥花%徐彧%李長龍%管濱
가경서%갈상화%서욱%리장룡%관빈
白血病%柔红霉素%去甲氧柔红霉素%治疗结果
白血病%柔紅黴素%去甲氧柔紅黴素%治療結果
백혈병%유홍매소%거갑양유홍매소%치료결과
Leukemia%Daunorubicin%Demethoxydaunor%Treatment outcome
目的 对比国产去甲氧柔红霉素( IDA)和进口柔红霉素(DNR)在急性白血病治疗中的的疗效和安全性.方法 68例急性白血病患者按随机数字表法分为IDA组35例和DNR组33例.IDA组35例患者中,急性髓细胞白血病用IA(国产IDA、阿糖胞苷)方案治疗,急性淋巴细胞白血病用VICLP(长春新碱、国产IDA、环磷酰胺、左旋门冬酰胺酶和泼尼松)方案治疗;同期DNR组33例患者中,急性髓细胞白血病用DA(进口DNR、阿糖胞苷)方案治疗,急性淋巴细胞白血病用VDCLP(长春新碱、进口DNR、环磷酰胺、左旋门冬酰胺酶和泼尼松)方案治疗.结果 IDA组完全缓解21例,部分缓解5例,总缓解率74.2%(26/35),DNR组完全缓解16例,部分缓解4例,总缓解率62.3 %(20/33),两组总缓解率差异无统计学意义( x2=0.89,P=0.50);IDA组缓解时间超过一年者占完全缓解患者的80%(17/21),而DNR组为37.5%(6/16),两组差异有统计学意义(x2=5.56,P=0.02).结论 国产IDA治疗急性白血病缓解率及长期缓解率均优于进口DNR,是疗效确切、安全可靠的抗白血病药物.
目的 對比國產去甲氧柔紅黴素( IDA)和進口柔紅黴素(DNR)在急性白血病治療中的的療效和安全性.方法 68例急性白血病患者按隨機數字錶法分為IDA組35例和DNR組33例.IDA組35例患者中,急性髓細胞白血病用IA(國產IDA、阿糖胞苷)方案治療,急性淋巴細胞白血病用VICLP(長春新堿、國產IDA、環燐酰胺、左鏇門鼕酰胺酶和潑尼鬆)方案治療;同期DNR組33例患者中,急性髓細胞白血病用DA(進口DNR、阿糖胞苷)方案治療,急性淋巴細胞白血病用VDCLP(長春新堿、進口DNR、環燐酰胺、左鏇門鼕酰胺酶和潑尼鬆)方案治療.結果 IDA組完全緩解21例,部分緩解5例,總緩解率74.2%(26/35),DNR組完全緩解16例,部分緩解4例,總緩解率62.3 %(20/33),兩組總緩解率差異無統計學意義( x2=0.89,P=0.50);IDA組緩解時間超過一年者佔完全緩解患者的80%(17/21),而DNR組為37.5%(6/16),兩組差異有統計學意義(x2=5.56,P=0.02).結論 國產IDA治療急性白血病緩解率及長期緩解率均優于進口DNR,是療效確切、安全可靠的抗白血病藥物.
목적 대비국산거갑양유홍매소( IDA)화진구유홍매소(DNR)재급성백혈병치료중적적료효화안전성.방법 68례급성백혈병환자안수궤수자표법분위IDA조35례화DNR조33례.IDA조35례환자중,급성수세포백혈병용IA(국산IDA、아당포감)방안치료,급성림파세포백혈병용VICLP(장춘신감、국산IDA、배린선알、좌선문동선알매화발니송)방안치료;동기DNR조33례환자중,급성수세포백혈병용DA(진구DNR、아당포감)방안치료,급성림파세포백혈병용VDCLP(장춘신감、진구DNR、배린선알、좌선문동선알매화발니송)방안치료.결과 IDA조완전완해21례,부분완해5례,총완해솔74.2%(26/35),DNR조완전완해16례,부분완해4례,총완해솔62.3 %(20/33),량조총완해솔차이무통계학의의( x2=0.89,P=0.50);IDA조완해시간초과일년자점완전완해환자적80%(17/21),이DNR조위37.5%(6/16),량조차이유통계학의의(x2=5.56,P=0.02).결론 국산IDA치료급성백혈병완해솔급장기완해솔균우우진구DNR,시료효학절、안전가고적항백혈병약물.
Objective To compare the effect and toxicity of domestic idarubicin (IDA) and imported daunorubicin (DNR) in the treatment of acute leukemia (AL).Methods According to the random number table method,68 patients were randomly divided in IDA group with 35 patients and DNR group with 33 patients.In IDA group,the patients with acute myelocytic leukemia were treated following IA scheme (domestic idataubicin plus cytosine arabinoside) and the patients with acute lymphoblastic leukemia were treated following VICLP scheme (vincristine,domestic idataubicin,cyclophosphamide,lasparaginase and prednisone).In DNR group,the patients with acute myelocytic leukemia were treated following DA scheme (imported daunorubicin plus cytosine arabinoside) and the patients with acute lymphoblastic leukemia were treated following VDCLP scheme (vincristine,imported daunorubicin,cyclophosphamide,lasparaginase and prednisone).Results In IDA group,21 patients achieved a complete remission(CR),5 patients achieved a partial remission(PR),with a 74.2 % (26/35) remission rate (RR).In DNR group,the remission rate was 62.3 % (20/33).No differences of the remission rate was found between the two groups (t =0.89,P =0.50).17 patients were found remission over one year in IDA group,and 6 patients were in DNR group.The difference was statistically significant between the two groups (x2 =5.56,P =0.02).Conclusion IDA is more effective than DNR in AL treatment.The higher RR and longer remission time are found in IDA group than DNR group.IDA is effective and safe in the treatment of AL.